PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 21, 2026

Metabolic syndrome in chronic schizophrenia: Cross-sectional hospital assessment of prolonged risperidone exposure.

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYimin WuJWJie WuDZDeng Zuobin

Discussion

Loading...

Member takes

Overview

The cross-sectional assessment shows reduced metabolic syndrome risk with risperidone in schizophrenia, suggesting the need for careful monitoring.

Key Points

  • This study aims to compare the risk of metabolic syndrome associated with long-term risperidone therapy versus olanzapine in patients with chronic schizophrenia.
  • Conducted a cross-sectional assessment of patients exposed to risperidone for an extended period.
  • Evaluated metabolic syndrome risk in comparison to olanzapine-treated patients.
  • Recommended regular metabolic monitoring and interventions for high-risk individuals.
  • Long-term risperidone therapy is linked to a lower risk of metabolic syndrome compared to olanzapine.
  • Regular metabolic monitoring is advised for patients on risperidone, especially those at high risk.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69e713decb99343efc98d4aahttps://doi.org/10.36721/pjps.2026.39.6.180.1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Metabolic Syndrome in Outpatients with Psychosis: a Comparative Study Between Long Acting Injectable Olanzapine and Risperidone2019 · 5 citations
  2. 2Incidence of hypercholesterolaemia and hyperglycaemia in schizophrenic patients: Atypical antipsychotic medication and clinical variables2024
  3. 3Metabolic Syndrome and Its Associated Factors Among Patients With Schizophrenia Treated With Second-Generation Antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia2024 · 2 citations
  4. 4Metabolic Syndrome in people treated with Antipsychotics (RISKMet): A multimethod study protocol investigating genetic, behavioural, and environmental risk factors2024 · 2 citations
  5. 5Metabolic effects of risperidone on patients with psychosis in a tertiary care hospital of Myanmar2024